Panacea Biotec Of India To Buy Stake In PharmAthene Of U.S.
This article was originally published in PharmAsia News
Executive Summary
India's Panacea Biotec plans to buy a large stake in PharmAthene, a U.S. biodefense company that makes products to counter biological and chemical threats. Panacea intends to buy 14.5 percent of the U.S. firm for $13.1 million through its Kelisia Holdings, a wholly owned subsidiary. The deal also gives Panacea the option of buying enough shares to give it practically a 20 percent stake in the American firm. (Click here for more